Alto Neuroscience (ANRO) Exchange Rate Effect (2023 - 2026)
Alto Neuroscience (ANRO) posted Exchange Rate Effect of -$16000.0 for Q1 2026, down 1500.0% sequentially from -$1000.0 in Q4 2025, and up 27.27% YoY from -$12571.4 in Q1 2025.
Alto Neuroscience (ANRO) Exchange Rate Effect (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Exchange Rate Effect for 4 years, with the latest figure at -$16000.0 in Q1 2026.
- Quarterly Exchange Rate Effect rose 27.27% year-over-year to -$16000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24000.0 (up 14.29% YoY) and the FY2025 annual result came in at -$30000.0, down 172.73% from the prior year.
- Exchange Rate Effect retreated to -$16000.0 in Q1 2026 per ANRO's latest filing, from -$1000.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $18000.0 in Q3 2023 and troughed at -$22000.0 in Q1 2025.
- A 4-year average of -$5000.0 and a median of -$5000.0 in 2024 frame the typical range for Exchange Rate Effect.
- The sharpest annual moves came in 2024 and 2025: Exchange Rate Effect jumped 73.68% in 2024, then sank 340.0% in 2025.
- Over 4 years, Exchange Rate Effect stood at $4000.0 in 2023, then jumped by 50.0% to $6000.0 in 2024, then slumped by 116.67% to -$1000.0 in 2025, then slumped by 1500.0% to -$16000.0 in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered -$16000.0, -$1000.0, and -$4000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | 4,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4,000.00 |
| Jun 30, 2026 | 4,000.00 |
| Mar 31, 2026 | -16,000.00 |
| Mar 31, 2026 | -16,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | -4,000.00 |
| Sep 30, 2025 | -4,000.00 |
| Jun 30, 2025 | -3,000.00 |
| Jun 30, 2025 | -3,000.00 |
| Mar 31, 2025 | -22,000.00 |
| Mar 31, 2025 | -22,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | -7,000.00 |
| Sep 30, 2024 | -7,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Mar 31, 2024 | -5,000.00 |